Calipso and CoherenSe are Riimex matrix's adaption by Capgemini Engineering - Former Altran Technologies - Made by FlexClip and Sabine Nkolo Atangana (Riimex Group's founder and CEO)
We're in commercial court with Capgemini Engineering - formerly Altran Technologies - and Jaguar Land Rover, because we couldn't reach an agreement following their use of the Riimex matrix to co-create CoherenSe, which is an adaptation of the Riimex matrix to the automotive sector.
They started using the matrix in 2015, and in 2016 we first charged them £14.4 million for a 10-year licence + £10M = £24 million).
It was a fixed price that didn't take into account a number of parameters that we didn't have, but it was also based on the principle that if they paid, it would allow us to avoid raising equity capital from investors, so that we could retain total control of the Riimex Group, while having the capital needed to respond to requests from other companies in the automotive sector, such as Mercedes, or to take part in actions for innovation in the automotive sector organised by Ferrari, for example, in collaboration with other partners.
7 years later, we are before the Commercial Court in proceedings that are now largely in our favour, and for which we hope for a decision in September 2023, after a multitude of postponed hearings.
Of course, the amounts claimed have necessarily increased, since not only have we missed out on the many opportunities that were opening up to us due to a lack of capital, but new information gathered from their various websites has enabled us to re-evaluate these amounts on the basis of the prices that were originally sent to them and the quantum that was also sent to them.
We are well aware that punitive damages do not exist in France, unlike in English-speaking countries such as the United States and the United Kingdom, but we still hope that the judges will take into account the loss of earnings, which was quite simply exponential. Capgemini Engineering has also been operating Riimex under the name Calipso since 2021... But here, their partners are Sanofi, Ypso-Facto, GPC Bio, the CEA and CentraleSupélec, because this adaptation is made for scientific research.
However, we haven't yet assessed the amounts they owe us for this new project, and we'd like to think that we won't have to wait another 7 years to reach an agreement.
Are we solving the risk?
Are we not solving the risk?
With the Riimex matrix, your risks are definitely your opportunities.
For more information, contact us at infos@riimexgroup.com or www.riimexgroup-database.com
© 2011 - 2023 Universe Innovation Holding Limited, Riimex Group. All rights reserved.
Comentários